Search research articles
Contact Us
Filters
Showing results (231-240 of 349) with videos related to
Page
of 35
Sort By:
The Lancet. Diabetes & Endocrinology
|
December 3, 2021
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
Subodh Verma, Nitish K Dhingra, Javed Butler, et al.
Circulation
|
November 7, 2022
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled
Subodh Verma, Nitish K Dhingra, Javed Butler, et al.
The New England Journal of Medicine
|
May 24, 2008
Bivalirudin during primary PCI in acute myocardial infarction
Gregg W Stone, Bernhard Witzenbichler, Giulio Guagliumi, et al.
Journal of the American College of Cardiology
|
March 23, 2019
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, et al.
JAMA Network Open
|
April 21, 2026
Invasive vs Conservative Strategy for Frail Older Patients With Myocardial Infarction: A Secondary Analysis of the SENIOR-RITA Randomized Clinical Trial
Francesca Rubino, Helen Mossop, David P Ripley, et al.
The American Journal of Cardiology
|
October 13, 2004
Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions
Eugenia Nikolsky, Roxana Mehran, Eve D Aymong, et al.
European Heart Journal
|
June 29, 2021
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Carolyn S P Lam, João Pedro Ferreira, Egon Pfarr, et al.
American Heart Journal
|
April 24, 2023
Fatal, ischemic and bleeding risk of patients meeting the selection criteria of the TWILIGHT trial: Insights from a large PCI registry
Alessandro Spirito, Won-Joon Koh, Samantha Sartori, et al.
Circulation. Cardiovascular Quality and Outcomes
|
January 5, 2019
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk
Usman Baber, Daniel E Leisman, David J Cohen, et al.
Journal of the American Heart Association
|
December 24, 2022
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
Muhammad Shahzeb Khan, Javed Butler, Stefan D Anker, et al.
Page
of 35
Search research articles
Search
Showing results (231-240 of 349) with videos related to
Sort By:
Page
of 35
The Lancet. Diabetes & Endocrinology
|
December 3, 2021
Empagliflozin in the treatment of heart failure with reduced ejection fraction in addition to background therapies and therapeutic combinations (EMPEROR-Reduced): a post-hoc analysis of a randomised, double-blind trial
Subodh Verma, Nitish K Dhingra, Javed Butler, et al.
Circulation
|
November 7, 2022
Empagliflozin in Black Versus White Patients With Heart Failure: Analysis of EMPEROR-Pooled
Subodh Verma, Nitish K Dhingra, Javed Butler, et al.
The New England Journal of Medicine
|
May 24, 2008
Bivalirudin during primary PCI in acute myocardial infarction
Gregg W Stone, Bernhard Witzenbichler, Giulio Guagliumi, et al.
Journal of the American College of Cardiology
|
March 23, 2019
Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT
Deepak L Bhatt, Ph Gabriel Steg, Michael Miller, et al.
JAMA Network Open
|
April 21, 2026
Invasive vs Conservative Strategy for Frail Older Patients With Myocardial Infarction: A Secondary Analysis of the SENIOR-RITA Randomized Clinical Trial
Francesca Rubino, Helen Mossop, David P Ripley, et al.
The American Journal of Cardiology
|
October 13, 2004
Impact of anemia on outcomes of patients undergoing percutaneous coronary interventions
Eugenia Nikolsky, Roxana Mehran, Eve D Aymong, et al.
European Heart Journal
|
June 29, 2021
Regional and ethnic influences on the response to empagliflozin in patients with heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial
Carolyn S P Lam, João Pedro Ferreira, Egon Pfarr, et al.
American Heart Journal
|
April 24, 2023
Fatal, ischemic and bleeding risk of patients meeting the selection criteria of the TWILIGHT trial: Insights from a large PCI registry
Alessandro Spirito, Won-Joon Koh, Samantha Sartori, et al.
Circulation. Cardiovascular Quality and Outcomes
|
January 5, 2019
Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk
Usman Baber, Daniel E Leisman, David J Cohen, et al.
Journal of the American Heart Association
|
December 24, 2022
Impact of Empagliflozin in Heart Failure With Reduced Ejection Fraction in Patients With Ischemic Versus Nonischemic Cause
Muhammad Shahzeb Khan, Javed Butler, Stefan D Anker, et al.
Page
of 35